Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer

References

• Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2014. National Cancer Institute.
   Google Scholar
• Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073-2087 e3. doi:10.1053/j.gastro.2009.12.064. PMID:20420947
   PubMed Web of Science ®Google Scholar
• Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 2010;7(3):153-62. doi:10.1038/nrclinonc.2009.237. PMID:20142816
   PubMed Web of Science ®Google Scholar
• Ciombor KK, Wu C, Goldberg RM. Recent Therapeutic Advances in the Treatment of colorectal cancer. Annual Rev Med. 2015;66(1):83-95. doi:10.1146/annurev-med-051513-102539
   PubMed Web of Science ®Google Scholar
• Paz MM, Zhang X, Lu J, Holmgren A. A New Mechanism of Action for the Anticancer Drug Mitomycin C: mechanism-based inhibition of thioredoxin reductase. Chem Res Toxicol. 2012;25(7):1502-1511. doi:10.1021/tx3002065. PMID:22694104
   PubMed Web of Science ®Google Scholar
• Wu K, Hinson SR, Ohashi A, Farrugia D, Wendt P, Tavtigian SV, Deffenbaugh A, Goldar D, Couch FJ. Functional evaluation and cancer risk assessment of BRCA2 Unclassified variants. Cancer Res. 2005;65(2):417-426. PMID:15695382
   PubMed Web of Science ®Google Scholar
• Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene. 2003;22(37):5784-5791. doi:10.1038/sj.onc.1206678. PMID:12947386
   PubMed Web of Science ®Google Scholar
• Lee H. Cycling with BRCA2 from DNA repair to mitosis. Exp Cell Res. 2014;329(1):78-84. doi:10.1016/j.yexcr.2014.10.008. PMID:25447315
   PubMed Web of Science ®Google Scholar
• Peng G, Lin SY. Exploiting the homologous recombination DNA repair network for targeted cancer therapy. World J Clin Oncol. 2011;2(2):73-9. doi:10.5306/wjco.v2.i2.73. PMID:21603316
   PubMedGoogle Scholar
• Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789-792. doi:10.1038/378789a0
   PubMed Web of Science ®Google Scholar
• Welcsh PL, King M-C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genetics. 2001;10(7):705-713. doi:10.1093/hmg/10.7.705
   PubMed Web of Science ®Google Scholar
• Sopik V, Phelan C, Cybulski C, Narod SA. BRCA1 and BRCA2 mutations and the risk for colorectal cancer. Clin Genetics. 2015;87(5):411-418. doi:10.1111/cge.12497
   PubMed Web of Science ®Google Scholar
• Romanowicz-Makowska H, Smolarz B, Langner E, Kozlowska E, Kulig A, Dziki A. Analysis of microsatellite instability and BRCA1 mutations in patients from hereditary nonpolyposis colorectal cancer (HNPCC) family. Pol J Pathol. 2005;56(1):21-6. PMID:15921010
   PubMedGoogle Scholar
• Dziadkowiec KN, Gasiorowska E, Nowak-Markwitz E, Jankowska A. PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Prz Menopauzalny. 2016;15(4):215-219. PMID:28250726
   PubMedGoogle Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152-1158. doi:10.1126/science.aam7344. PMID:28302823
   PubMed Web of Science ®Google Scholar
• Seton-Rogers S. Targeted therapies: expanding the use of PARP inhibitors. Nat Rev Cancer. 2017;17(7):397
   Google Scholar
• Sahu A, Prabhash K, Noronha V, Joshi A, Desai S. Crizotinib: A comprehensive review. South Asian J Cancer. 2013;2(2):91-7. doi:10.4103/2278-330X.110506. PMID:24455567
   PubMedGoogle Scholar
• Qian H, Gao F, Wang H, Ma F. The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials. BMC Cancer. 2014;14(1):683. doi:10.1186/1471-2407-14-683. PMID:25239305
   PubMed Web of Science ®Google Scholar
• Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3(1 Suppl):S7-S19. doi:10.1177/1758834011422556. PMID:22128289
   PubMedGoogle Scholar
• Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 2006;6(8):637-645. doi:10.1038/nrc1912. PMID:16862193
   PubMed Web of Science ®Google Scholar
• Piguet AC, Medova M, Keogh A, Gluck AA, Aebersold DM, Dufour JF, Zimmer Y. Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer. Genes Cancer. 2015;6(7-8):317-27. PMID:26413215
   PubMedGoogle Scholar
• Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3(1 Suppl):S21-35. doi:10.1177/1758834011422557. PMID:22128285
   PubMedGoogle Scholar
• Gayyed MF, Abd El-Maqsoud NMR, El-Heeny AAE-H, Mohammed MF. c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases. J Gastrointest Oncol. 2015;6(6):618-27. PMID:26697193
   PubMed Web of Science ®Google Scholar
• Mughal A, Aslam HM, Sheikh A, Khan AM, Saleem S. c-Met inhibitors. Infect Agent Cancer. 2013;8(1):13. doi:10.1186/1750-9378-8-13. PMID:23566349
   PubMed Web of Science ®Google Scholar
• Sharma N, Adjei AA. In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs. Ther Adv Med Oncol. 2011;3(1 Suppl):S37-50. doi:10.1177/1758834011423403. PMID:22128287
   PubMedGoogle Scholar
• Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006;12(12):3657-60. doi:10.1158/1078-0432.CCR-06-0818. PMID:16778093
   PubMed Web of Science ®Google Scholar
• Hojjat-Farsangi M. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Int J Mol Sci. 2014;15(8): 13768-801. doi:10.3390/ijms150813768. PMID:25110867
   PubMed Web of Science ®Google Scholar
• Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Seminars Oncol. 2006;33(4):407-420. doi:10.1053/j.seminoncol.2006.04.005.
   PubMed Web of Science ®Google Scholar
• Phelan CM, Iqbal J, Lynch HT, Lubinski J, Gronwald J, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, et al. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. Br J Cancer. 2014;110(2):530-4. doi:10.1038/bjc.2013.741. PMID:24292448
   PubMed Web of Science ®Google Scholar
• Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, et al. BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Oncotarget. 2017;8(25):39945-62. PMID:28591715
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-921. doi:10.1038/nature03445. PMID:15829967
   PubMed Web of Science ®Google Scholar
• Scully R, Xie A. Double strand break repair functions of histone H2AX. Mutat Res. 2013;750(1-2):5-14. doi:10.1016/j.mrfmmm.2013.07.007. PMID:23916969
   PubMed Web of Science ®Google Scholar
• Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11(12):834-848. doi:10.1038/nrm3012. PMID:21102609
   PubMed Web of Science ®Google Scholar
• Yang RL, Mick R, Lee K, Graves HL, Nathanson KL, Domchek SM, Kelz RR, Zhang PJ, Czerniecki BJ. DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3. J Translational Med. 2015;13:335. doi:10.1186/s12967-015-0698-3
   PubMed Web of Science ®Google Scholar
• Zenali M, deKay J, Liu Z, Hamilton S, Zuo Z, Lu X, Bakkar R, Mills G, Broaddus R. Retrospective review of MET gene mutations. Oncoscience. 2015;2(5):533-41. doi:10.18632/oncoscience.161. PMID:26097886
   PubMedGoogle Scholar
• Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang Hl, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, 4th, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016;22(2):194-201. doi:10.1038/nm.4032. PMID:26779812
   PubMed Web of Science ®Google Scholar
• Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs. 2013;73(18):2031-51. doi:10.1007/s40265-013-0142-z. PMID:24288180
   PubMed Web of Science ®Google Scholar
• Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5(4):387-393. doi:10.1016/j.molonc.2011.07.001. PMID:21821475
   PubMed Web of Science ®Google Scholar
• Medova M, Aebersold DM, Zimmer Y. MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. Int J Cancer. 2012;130(3):728-34. doi:10.1002/ijc.26058. PMID:21400509
   PubMed Web of Science ®Google Scholar
• Medova M, Aebersold DM, Zimmer Y. The molecular crosstalk between the MET receptor tyrosine kinase and the DNA Damage Response-Biological and Clinical Aspects. Cancers (Basel). 2013;6(1):1-27. doi:10.3390/cancers6010001. PMID:24378750
   PubMed Web of Science ®Google Scholar
• Medova M, Aebersold DM, Blank-Liss W, Streit B, Medo M, Aebi S, Zimmer Y. MET inhibition results in DNA breaks and synergistically sensitizes tumor cells to DNA-Damaging agents potentially by breaching a damage-induced checkpoint arrest. Genes Cancer. 2010;1(10):1053-62. doi:10.1177/1947601910388030. PMID:21779429
   PubMedGoogle Scholar